The Attractions of PYC's pipeline, page-22

Praying for PYC to have favor with the FDA who have only had a handful of CPP-PMO IND before them, and probably the first ocular application of this nature.

Rohan uses the word “white space” this applies to both the science, regulatory and patient market = new frontier to be forged, and potentially usher in a unique leadership role for PYC to play in this new corner of the biotech-pharma industry.

as a side note, I noticed 17c strike price for new options; this is comforting for me as it indicates management internal valuation - am not sure how long the current 60% discount to previous cap raise price will persist - it’s a great deal for beneficiaries.

I do hope to breakeven on this tranche once FDA approves, not that I’ll be selling - but it also provides great motivation as these options for employees can go to being $1 in the moment I believe if all three programs make receive IND, and VP-001 show some efficacy which enhances look through valuation for the pipeline.